Business
Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated
About this update from Neurogene Inc.
[{"type":"text","content":"SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial results on Thursday, March 25, 2021 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows: Date: March 25, 2021Time: 1:30 p.m. Pacific / 4:30 p.m. EasternToll-free: (866) 357-7878International: (315) 625-3088Conference ID: 2666855Webcast URL: http://investor.neoleukin.com/events The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the event and will be available for replay for at least 30 days after the event. About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com. Safe Harbor / Forward-Looking Statements This press release contains \"forward-looking\" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201 and planned development activities and timelines. Forward-looking statements can be identified by words such as: \"anticipate,\" \"intend,\" \"plan,\" \"goal,\" \"seek,\" \"believe,\" \"project,\" \"estimate,\" \"expect,\" \"strategy,\" \"future,\" \"likely,\" \"may,\" \"should,\" \"will\" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks an...